Cordis Corporation Release: Economic Model Presented at TCT 2010 Suggests That the Use of CYPHER Drug Eluting Stent May Result in Substantial Cost Savings When Compared to Other Drug Eluting Stents

BRIDGEWATER, N.J.--(BUSINESS WIRE)--New analysis presented at the Transcatheter Cardiovascular Therapeutics meeting (TCT 2010) in Washington, DC, indicates that the broad use of CYPHER® Sirolimus-eluting coronary stent in patients with diabetes would result in substantial cost savings, as compared to the use of everolimus-eluting stents (EES), paclitaxel-eluting stents (PES), or zotarolimus-eluting stents (ZES). Diabetic patients are a population at elevated risk of needing repeat coronary procedures and also pose a significant cost burden to the health care system.